Inhomogeneous dose escalation for NSCLC: Full dosimetric analysis of the phase III NARLAL2 trial

被引：0
|
作者：
Lutz, Christina M. [1 ]
Nielsen, Tine B. [2 ]
Lund, Mikkel D. [3 ]
Schytte, Tine [2 ]
Hansen, Torben S. [3 ]
Hoffmann, Lone [1 ,4 ]
Ottosson, Katarina W. [5 ]
Peucelle, Cecile [6 ]
Rusten, Espen [7 ]
Levin, Nina [8 ]
Brink, Carsten [2 ]
Gronberg, Bjorn H. [8 ,9 ]
Haakensen, Vilde D. [7 ]
Hansen, Olfred [2 ]
Khalil, Azza A. [1 ,4 ]
Knap, Marianne M. [1 ]
Kristiansen, Charlotte [3 ]
Nielsen, Morten [2 ]
Persson, Gitte F. [5 ,10 ]
Pohl, Mette [6 ]
Thing, Rune S. [3 ]
Moller, Ditte S. [1 ,4 ]
机构：
[1] Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark
[2] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[3] Univ Hosp Southern Denmark, Vejle Hosp, Dept Oncol, Vejle, Denmark
[4] Aarhus Univ, Dept Clin Med, Aarhus, Denmark
[5] Copenhagen Univ Hosp Herlev & Gentofte, Dept Oncol, Herlev, Denmark
[6] Rigshosp, Dept Oncol, Copenhagen, Denmark
[7] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[8] St Olavs Hosp, Dept Oncol, Trondheim, Norway
[9] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway
[10] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
来源：
RADIOTHERAPY AND ONCOLOGY | 2024年 / 194卷
关键词：
NSCLC; dose escalation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2381
引用
收藏
页码：S1736 / S1739
页数：5
相关论文
共 50 条
  • [1] Heterogeneous FDG-guided dose escalation of locally advanced NSCLC, the NARLAL2 phase III trial
    Moeller, D. S.
    Hoffmann, L.
    Lutz, C. M.
    Nielsen, T. B.
    Brink, C.
    Appelt, A. L.
    Lund, M. D.
    Nielsen, M. S.
    Ottosson, W.
    Khalil, A. A.
    Knap, M. M.
    Hansen, O.
    Schytte, T.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S259 - S259
  • [2] Quality assurance in implementing a national dose escalation trial in NSCLC - report from NARLAL2
    Nielsen, T. B.
    Brink, C.
    Moeller, D. S.
    Hoffmann, L.
    Lutz, C. M.
    Appelt, A. L.
    Lund, M. D.
    Nielsen, M. S.
    Ottosson, W.
    Khalil, A. A.
    Knap, M. M.
    Hansen, O.
    Schytte, T.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S916 - S917
  • [3] The NARLAL2 dose escalation trial: dosimetric implications of inter-fractional changes in organs at risk
    Hoffmann, Lone
    Knap, Marianne Marquard
    Khalil, Azza Ahmed
    Lutz, Christina Maria
    Moller, Ditte Sloth
    ACTA ONCOLOGICA, 2018, 57 (04) : 473 - 479
  • [4] The NARLAL2 Phase III Trial: Heterogeneous FDG-Guided Dose Escalation of Advanced NSCLC. A Clinical Trial by the Danish Lung Cancer Group
    Moller, Ditte Sloth
    Andersen, Jon L.
    Appelt, Ane L.
    Brink, Carsten
    Hansen, Olfred
    Hoffmann, Lone
    Jensen, Nikolaj K. G.
    Josipovic, Mirjana
    Khalil, Azza Ahmed
    Knap, Marianne Marquard
    Lund, Mikkel D.
    Lutz, Christina M.
    Nielsen, Martin S.
    Nielsen, Svetlana K.
    Nielsen, Tine B.
    Nyhus, Christa H.
    Ottosson, Wiviann
    Persson, Gitte F.
    Sibolt, Patrik
    Wedervang, Kim
    Schytte, Tine
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S286 - S287
  • [5] Overall survival following heterogeneous FDG-guided dose-escalation for locally advanced NSCLC in the international phase III NARLAL2 trial.
    Schytte, Tine
    Kristiansen, Charlotte
    Khalil, Azza
    Hansen, Olfred
    Land, Lotte Holm
    Brink, Carsten
    Nielsen, Tine
    Nielsen, Morten
    Hansen, Torben Schjodt
    Poehl, Mette
    Persson, Gitte
    Haakensen, Vilde
    Halvorsen, Tarje Onsoien
    Sundby, Filippa
    Schmidt, Hjoerdis
    Hoffmann, Lone
    Appelt, Ane L.
    Moller, Ditte Sloth
    Lutz, Christina
    Knap, Marianne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8069 - LBA8069
  • [6] Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study
    Moller, Ditte Sloth
    Nielsen, Tine Bjorn
    Brink, Carsten
    Hoffmann, Lone
    Lutz, Christina Maria
    Lund, Mikkel Drogemuller
    Hansen, Olfred
    Schytte, Tine
    Khalil, Azza Ahmed
    Knap, Marianne Marquard
    Nyhus, Christa Haugaard
    Ottosson, Wiviann
    Sibolt, Patrik
    Borissova, Svetlana
    Josipovic, Mirjana
    Persson, Gitte
    Appelt, Ane Lindegaard
    RADIOTHERAPY AND ONCOLOGY, 2017, 124 (02) : 311 - 317
  • [7] Safe inhomogeneus RT dose escalation in locally advanced NSCLC, -interim results from NARLAL2
    Schytte, T.
    Nielsen, T.
    Moeller, D.
    Hoffmann, L.
    Khalil, A.
    Knap, M.
    Lund, M.
    Nyhus, C.
    Hansen, T.
    Ottosson, W.
    Borissova, S.
    Appelt, A.
    Brimk, C.
    Hansen, O.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S388 - S389
  • [8] Full-dose SBRT forthe primarytumour in stage III NSCLC: a promising and safe way to selective dose escalation?
    Le Pechoux, Cecile
    Botticella, Angela
    Levy, Antonin
    LANCET ONCOLOGY, 2025, 26 (01): : 3 - 5
  • [9] Phase lb Trial of Afatinib and BI 836845 in Advanced NSCLC: Dose Escalation and Safety Results
    Park, Keunchil
    Cho, Byoung Chul
    Lee, Ki Hyeong
    Su, Wu-Chou
    Kim, Sang-We
    Lin, Chia-Chi
    Huang, Dennis Chin-Lun
    Jung, Helen Hayoun
    Geng, Yuan
    Tan, Daniel Shao Weng
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1187 - S1188
  • [10] Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine
    Allen, AM
    Zalupski, MM
    Robertson, JM
    Eckhauser, FE
    Simone, D
    Brown, D
    Hejna, G
    Normolle, D
    Lawrence, TS
    McGinn, CJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (05): : 1461 - 1467
12345